Insights into how adeno-squamous transition drives KRAS inhibitor resistance.
Cancer Cell
; 42(3): 330-332, 2024 Mar 11.
Article
in En
| MEDLINE
| ID: mdl-38471455
ABSTRACT
The histologic transformation of adenocarcinoma (ADC) to squamous cell carcinoma (SCC), known as adeno-squamous transition or AST, is frequently observed in patients with lung cancer undergoing cancer therapy. In this issue, Tong and colleagues investigate genetic and epigenetic mechanisms that drive AST to confer resistance to KRAS inhibitors in preclinical models and patients.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Squamous Cell
/
Adenocarcinoma
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Cancer Cell
Journal subject:
NEOPLASIAS
Year:
2024
Type:
Article
Affiliation country:
United States